The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR - An update of progress in stroke

被引：12

作者：

Palmer, GC ^{[1
]}

Cregan, EF ^{[1
]}

Bialobok, P ^{[1
]}

Sydserff, SG ^{[1
]}

Hudzik, TJ ^{[1
]}

McCarthy, DJ ^{[1
]}

机构：

[1] Astra Arcus USA, Rochester, NY 14602 USA

来源：

NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE | 1999年 / 890卷

关键词：

D O I：

10.1111/j.1749-6632.1999.tb08020.x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Use-dependent N-methyl-D-aspartate (NMDA) receptor antagonists protect neurons from the lethal consequences of excessive stimulation by excitatory amino acids, Clinical development of high-affinity compounds such as MK801 have been limited due to untoward side effects. Toward this end, the lower-affinity use-dependent NMDA antagonists have greater margins of safety and have advanced to clinical trials for stroke, epilepsy, head trauma and chronic neurodegenerative disorders. AR-R 15896AR is currently in Phase II trials for stroke and has been repeatedly demonstrated to afford neuroprotection in a variety of in vivo and in vitro models associated with ischemia/excitotoxic conditions.

引用

页码：406 / 420

页数：15

共 42 条

[1] REORGANIZATION OF THE CYTOSKELETON IN RAT NEURONS FOLLOWING STIMULATION WITH EXCITATORY AMINO-ACIDS INVITRO [J].